Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.

Fezolinetant eases vasomotor symptoms, improves quality of life

26 Aug 2020

Treatment with oral fezolinetant leads to a reduction in vasomotor symptoms (VMS) with large parallel improvements in quality of life, according to data from the phase IIb VESTA trial.

In the 12-week trial, 352 postmenopausal women with VMS were randomly assigned to the following treatment groups: fezolinetant 15 mg (n=45), 30 mg (n=43), 60 mg (n=45), and 90 mg (n=45) twice daily (BID); or 30 mg (n=43), 60 mg (n=45), and 120 mg (n=44) once daily (QD); or placebo (n=43). At baseline, the women were aged 40–65 years and had body mass index of 18–38 kg/m2. They reported having 50 moderate-to-severe VMS per week.

Compared with placebo, all fezolinetant doses were associated with marked reductions in VMS frequency at weeks 4 (mean, −1.9 to −3.5) and 12 (mean, −1.8 to −2.6; p<0.05). Likewise, severity decreased by a mean of 0.4 to 1.0 with all doses (p<0.05) at week 4 and by 0.2 to 0.6 with the 60-mg and 90-mg BID and 60-mg QD (p<0.05) at week 12.

VMS frequency reductions were accompanied by clinically meaningful changes in patient-reported outcomes. For instance, all doses of fezolinetant improved scores on the Hot Flash-Related Daily Interference Scale at weeks 4 (placebo: −2.2; fezolinetant: range, −2.5 to −3.8) and 12 (placebo: −2.9; fezolinetant: range, −3.3 to −4.3), as well as on the Menopause-Specific Quality of Life questionnaire (week 4, placebo: −1.8; fezolinetant: range, −1.9 to −3.6; week 12, placebo: −2.3; fezolinetant: range, −2.9 to −4.4).

Also, Greene Climacteric Scale-VMS domain scores improved for most fezolinetant doses at both time points (week 4, placebo: −1.7; fezolinetant: range, −2.1 to −3.3; week 12, placebo: −2.1; fezolinetant: range, −2.7 to −3.6).

Treatment-emergent adverse events were mostly mild or moderate, occurring similarly across all fezolinetant groups.

The findings suggest that the neurokinin 3 receptor antagonist fezolinetant, a nonhormonal therapy, may be an attractive treatment option in women with moderate-to-severe VMS associated with menopause, which could translate into meaningful improvements in quality of life, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.